Background: To determine the correlation of cyclin-dependent kinase inhibitor 1B (p27) expression with clinicopathologic features in nasopharyngeal carcinoma (NPC), including patient prognosis. Methods: Real-time PCR and immunohistochemistry were used to examine the mRNA and protein expressions of p27 in NPC and nasopharyngeal tissues. The relationship of p27 expression levels with clinical features and prognosis of NPC patients was analyzed. Results: The expression level of p27 mRNA was markedly lower in NPC tissues than that in the nasopharyngeal tissues (P = 0.0006). Specific p27 protein staining by immunohistochemistry was found in the nuclei and cytoplasm of nasopharyngeal and malignant epithelial cells but decreased expression was observed in NPC samples compared to normal epithelium samples (P = 0.002). In addition, low levels of p27 protein were inversely correlated with the status of T classification (p = 0.002) and clinical stage (p = 0.019) of NPC patients. Patients with lower p27 expression had a significantly shorter overall survival time than did patients with high p27 expression. Multivariate analysis suggested that the level of p27 expression was not an independent prognostic indicator (p = 0.682) for NPC survival.
Background
Nasopharyngeal carcinoma (NPC) is a squamous cell carcinoma derived from mucosal epithelium of the nasopharynx correlated with EBV infection, environmental factors and genetic aberrance. Among them, EBV infection is the most important for NPC, when other cancers in upper digestive tract have something with to do with it [1] . The initiation and progression of NPC is a complex and consecutive process with the participation of many important genes [2] [3] [4] [5] . In a previous study, we used cDNA microarray to detect differentially expressed genes among NPC and nasopharyngeal tissues (NP) and observed that expression of p27, a gene encoding cyclindependent kinase inhibitor 1B, was indicated to be significantly reduced in NPC tissues and cells, hinting its potentially suppressive role in NPC pathogenesis [6] (Additional file 1: Figure S1 ).
P27 is an enzyme inhibitor that in humans is encoded by the CDKN1B gene. It encodes a protein which belongs to the Cip/Kip family of cyclin dependent kinase (Cdk) inhibitor proteins. In previous investigations, downexpression of P27 had been indicated in many tumor types, including lung cancer [7] , hepatocellular carcinoma [8] , gastric cancer [9] , colorectal cancer [10] et al., which induced the progression and poor prognosis of these tumors. Further, p27 was observed to act as a significant role in suppressing tumor pathogenesis [11, 12] . Based on the above reports mentioned, p27 was taken as an important gene participating in tumor pathogenesis. The role p27 plays in NPC has also been reported in several references [13, 14] .p27 was found the low expression level may contribute to the aggressive behavior of NPC by immunohistochemistry.
To further clarify its role in NPC pathogenesis, the present study was to investigate the expression status of mRNA and protein in much more NPC cases and NP cases than those of the previous literatures, and then analyze the potential associations of this protein with clinicopathological features and overall survival rate in 130 cases of NPC patients.
Materials and methods

Cell culture
Seven (7) NPC cell lines including 5-8 F, 6-10B, CNE2, C666-1, HONE1, HNE1, and SUNE1 were maintained in RPMI 1640 supplemented with 10% newborn calf serum (NBCS) (PAA Laboratories, Inc, Austria).
Sample collection
Sixty-one (61) primary fresh NPC samples and 20 noncancerous fresh nasopharyngeal samples were collected at the time of diagnosis before any therapy at the People's Hospital of Zhongshan City, China from 2012 to 2013. All fresh samples were immediately preserved in liquid nitrogen. Thirty-five (35) NP tissues and 130 undifferentiated NPC paraffin-embedded specimens with clinic and prognosis information from 2003 to 2006 were obtained from the People's Hospital of Zhongshan City, and their age ranging from 21 to 80 years (median, 49.6 years). Brief clinical data of these NPC cases were given in Table 1 . For the use of these clinical materials for research purposes, prior consent from the patients and approval from the Ethics Committees of these two hospitals were obtained. All specimens had confirmed pathological diagnosis and were staged according to the 1997 NPC staging system of the UICC.
Real-time PCR
Real-time PCR was used to measure the expression of p27 mRNA in fresh NPC cells, NPC tissues, and NP tissues using SYBR Premix Ex Taq (Takara, Japan) with an Mx3000P real-time PCR system (Stratagene, La Jolla, CA, USA) and the reaction was repeated three times. The sequence for sense primer was 5′-GAAGCCTGGC CTCAGAAGAC-3′, and for antisense primer was 5′-TC CAACGCTTTTAGAGGCAGAT-3′. ARF gene was used as an internal control [3] .
Immunohistochemistry
Immunohistochemistry was utilized to examine the protein expression of p27 with rabbit anti-human p27 antibody (1:100) (Santa Cruz Biotechnology, USA) according to the previous description [2] . Sections were visualized with DAB and counterstained with hematoxylin, mounted in neutral gum, and analyzed using a bright field microscope.
Evaluation of staining
The immunohistochemically stained tissue sections of p27 in cytoplasm were reviewed and scored separately by two pathologists blinded to the clinical parameters. Expression of p27 in the nucleus and in the cytoplasm was independently evaluated and scored as previously described [12] . The sum of the cytoplasm and nuclear staining scores was used as the final staining score for p27. For statistical analysis, a final staining score of 0-6 or 7-12 was respectively considered to be low or high expression.
Statistical analyses
All statistical analyses were performed using SPSS 13.0 and Graphpad softwares. Data were presented as mean ± SD. Two-tailed Student's t test was used for comparisons of 2 independent groups. The χ 2 test was used to analyze the relationship between the levels of p27 expression and clinicopathologic characteristics. Survival curves were plotted using the Kaplan-Meier method and compared using the log-rank test. The significances of various variables in survival were analyzed using multivariate cox proportional hazards model. A P value of less than 0.05 was considered statistically significant.
Results
P27 mRNA is expressed at low levels in NPC tissue
In order to assess the role of p27 in NPC, we performed real-time PCR to measure the expression of p27 mRNA transcripts in 61 fresh NPC tissues and 20 fresh collected normal nasopharyngeal tissues. Compared with normal nasopharyngeal tissues, NPC cells and tissues showed reduced expression levels of p27 mRNA (p = 0.0006) ( Figure 1A ). Furthermore, decreased p27 mRNA expression was observed in clinical stage III-IV compared to clinical stage I-II samples ( Figure 1B ) (p = 0.0103). However, we did not find the significantly differential expression of p27 mRNA in T3-4 and N2-3 compared to T1-2 and N0-1 ( Figure 1C, D) .
Immunohistochemical analysis of p27 protein expression in NPC and nasopharynx tissues
We measured the expression levels and subcellular localization of p27 protein in 130 archived paraffinembedded NPC samples and 35 NP samples using immunohistochemical staining (Figure 2A-D) . Specific p27 protein staining was detected in the nuclei and cytoplasm of non-cancerous and malignant epithelial cells (Figure 2A, B) . Decreased expression of p27 was observed in NPC samples compared to NP tissues (P = 0.002) ( Table 2) .
Relationship between clinicopathological characteristics and p27 expression in NPC patients
The relationship between clinicopathological characteristics and p27 expression levels in individuals with NPC is summarized in Table 1 . We did not find a significant association between p27 expression levels with patient's age, sex, smoking, disease recurrence, N classification, and M classification in 130 NPC cases. However, we observed that the expression level of p27 was inversely correlated with tumor size (T classification) (P = 0.002) and clinical stage (I-II vs. III-IV) (P = 0.019) in NPC patients (Table 1) .
Survival analysis
To investigate the prognostic value of p27 expression for NPC, we assessed the association between the levels of P27 expression and patients' survival using Kaplan-Meier analysis with the log-rank test. In 130 NPC cases with prognosis information, we observed that the level of p27 protein expression was significantly correlated with the overall survival of NPC patients (Figure 3) . Patients with high levels of p27 expression had better survival than those with low levels of P27 expression (P = 0.026). In addition, we also observed that the patients with higher P27 protein expression had longer survival time N0-N1 (P = 0.011) classification (Figure 4 ). Univariate analyses showed that patient survival was also significantly correlated with radiotherapy, T, N, M classifications, clinical stages and the expression of p27 (P = 0.005, P<0.001, P<0.001, P<0.001, P<0.001, and P = 0.032 respectively). To determine whether p27 is an independent prognostic factor for NPC, we performed multivariate analysis of P27 protein expression levels adjusted for age, gender, smoking status, T classification, N classification, M classification, and clinical stages of NPC patients. These results showed that the level of P27 expression was not an independent prognostic factor for NPC (P = 0.682) ( Table 3) .
Discussion
NPC is a unique malignant head/neck cancer with remarkably distinctive ethnic and geographic distribution among the world.Though there are some other neoplasms such as lymphoma, carcinoma of salivary gland and rare melanotic disease [15] , NPC is the most common in nasopharyngeal region. It is a disease with disorder of cell cycle and uncontrolled growth due to abnormal expression of cell cycle factors [4, 6, 16] . P27, a key cell cycle protein kinase inhibitor, formed a complex with CCND1 and CDK4 that prevents CDK4 from adding phosphate residues to its principal substrate, the retinoblastoma (pRb) protein and blocks the cell-cycle G1/S transition. Furthermore, p27 is able to bind other Cdk proteins when it connected to cyclin subunits such as Cyclin A/Cdk2 and Cyclin E/Cdk2 and suppress the transition of cell cycle. Decreased expression of p27 has been indicated in many tumors, including lung cancer [17] , bladder cancer [18] , melanoma [19] , and ovarian cancer [20] , prostate cancer [21] , which was associated with the unfavorable clinical parameters and poor outcomes of these tumors. However, the role of p27 is still unclear in NPC. In a previous investigation, we found the significantly attenuated levels of p27 mRNA in NPC tissues and cells compared to NP tissues [6] by gene microarray analysis. In this study, we validated the significantly differential expression of mRNA in NPC tissues and NPC cells compared to NP tissues by real-time PCR. Our reports were similar with the investigation of p27 mRNA expression in other tumors [17] [18] [19] . Furthermore, we also found that reduced mRNA p27 expression was shown in clinical stage of III-IV compared to clinical stage of I-II. These results preliminarily suggested p27 as a potentially suppressive gene involved in the pathogenesis of NPC.
In subsequent exploration, we observed that p27 protein was a co-expression factor of cytoplasm and nucleus in NPC tissues and nearly a half of NPC cases showed nuclear expression of p27. In line with the mRNA expression examination, p27 protein expression was significantly down-regulated in NPC tissues compared to NP tissues. This result further provided evidence to support p27 as a candidate suppressor in NPC. Further, we analyzed the correlation of p27 protein expression with clinical features of NPC patients. We found that although p27 protein expression was not associated with patient's age, sex, smoking, N classification (lymph node metastasis) or M classification (distant metastasis), it was positively correlated with T classification (tumor size) and clinical stage. This result was similar to our report of p27mRNA expression of in NPC. Furthermore, we presented the evidence that protein expression of p27 protein in NPC was inversely correlated with patient's overall survival time. Patients with high protein expression of p27 had an overall longer survival time.
Our results here suggest that p27 protein expression is taken as a tumor suppressor inhibiting the pathogenesis of NPC.
Furthermore, survival prognosis was assessed by stratification analysis against different T classification, N classification, M classification, and clinical stage. We observed that p27 protein expression was only positively associated with the survival time for NPC patients in N0-1 classification. Patients with high p27 expression had better prognosis than those of negative nuclear expression. These results hinted that p27 expression is a good biomarker for evaluating the prognosis of NPC patients with N0-1 classification.
Finally, we evaluate the possibility of p27 protein expression as an independent prognostic factor. According to univariate analysis, patient's overall survival is inversely proportional to T/N/M classification, clinical stage, but positively correlated with p27 protein expression and radiotherapy. Multivariate analyses showed that nuclear expression of p27 protein was not an independent predictor of prognosis for NPC patients regardless of its patients' disease status. This result was not consistent with the reports from other tumors including breast cancer [22] and glioma [23] etc.
In summary, our results provide evidence that expression of p27 may be involved in the clinical progression and poor prognosis of NPC patients. However, it could not serve as a potential independent prognostic factor for NPC patients.
Conclusion
In summary, our study demonstrated that the expression level of p27 was significantly reduced in NPC and correlated with the malignant status and poor prognosis for NPC patients. Due to the limited sample size of patients in our investigation, further studies are needed to verify these findings and establish the role of p27 as a reliable clinical predictor for the outcome of NPC patients. 
